General
publicado em 08/07/2011 às 18h00:00
   Dê o seu voto:

Anvisa approves long-acting drug to treat schizophrenia

New drug has the potential to reduce disease symptoms, prevent relapses and thus avoid hospitalizations

 
font size
A-
A+

Some pieces of information on this page may have been automatically translated. Makernews is not responsible for the irregularities resulting from these translations. When in doubt,      consult the original text.



The National Health Surveillance Agency (Anvisa) approved a new drug based on paliperidone palmitate for acute and maintenance treatment of schizophrenia in adults. It is a second-generation antipsychotic, injectable, extended-release and monthly usage to be made available in Brazil. The new drug has the potential to reduce symptoms, prevent relapses and thus avoid hospitalizations.

Schizophrenia affects about 1% of the adult population in the country, or nearly two million Brazilians. With each relapse, the patient has a lot of damage that lead to losses in real-life consequences of the financial and professional carrier of the disease and the family. In addition, there may be an increase in suicide rates.

The new product will be an important ally in the treatment of schizophrenia in Brazil. Their effectiveness and characteristics associated with greater ease of use can provide a greater adherence to treatment, reducing the chance of relapse. Said Jose Carlos Appolinário, medical director of Janssen-Cilag Pharmaceuticals.

Source: Isaude.net
   Palavras-chave:   Schizophrenia    Paliperidone palmitate    Anvisa    Medicine   
  • Share this pageShare this page
  • Share this pageCorrect
  • ShareShare
  • AlertAlert
Reduced link: 
  • You are recommending this story: Anvisa approves long-acting drug to treat schizophrenia
  • Fill in the following form to send your recommendation to your friend:

  • You are suggesting a correction for this story: Anvisa approves long-acting drug to treat schizophrenia


Receba notícias do iSaúde no seu e-mail de acordo com os assuntos de seu interesse.
Seu nome:
Seu email:
Desejo receber um alerta com estes assuntos:
Schizophrenia    paliperidone palmitate    Anvisa    medicine   
Comments:
Comment
Leave your comment
Close
(Required fields are marked with an *)

(Your email address will never be published or shared.)

Enter the letters and numbers below and click in the button "send"

  • Twitter iSaúde
advertising
Informe Saúde printed version

Recommend the portal
Close [X]
  • You are recommending this story: http://www.isaude.net
  • Fill in the following form to send your recommendation to your friend:

RSS news from the portal  iSaúde.net
Get the newsletter of the portal  iSaúde.net
Recommend the portal iSaúde.net
News from  iSaúde.net in your blog or website.
Get news on the subject of your interest.
© 2000-2011 www.isaude.net Todos os direitos reservados.